Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Genomics02:02

Genomics

Genomics is the science of genomes: it is the study of all the genetic material of an organism. In humans, the genome consists of information carried in 23 pairs of chromosomes in the nucleus, as well as mitochondrial DNA. In genomics, both coding and non-coding DNA is sequenced and analyzed. Genomics allows a better understanding of all living things, their evolution, and their diversity. It has a myriad of uses: for example, to build phylogenetic trees, to improve productivity and...
Biostatistics: Overview01:20

Biostatistics: Overview

Biostatistics plays a crucial role in understanding and analyzing data in healthcare and biology. Biostatisticians conduct experiments, gather evidence, and draw meaningful conclusions using statistical methods and techniques. Different variables form the foundation of biostatistical analysis, allowing researchers to understand and interpret data effectively. These variables are classified into different types, each serving a specific purpose in statistical analysis.
Discrete variables are...
Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis00:59

Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis

Noncompartmental analyses offer an alternative method for describing drug pharmacokinetics without relying on a specific compartmental model. In this approach, the drug's pharmacokinetics are assumed to be linear, with the terminal phase log-linear. This assumption allows for simplified analysis and interpretation of the drug's behavior in the body.
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This relationship...
Statistical Software for Data Analysis and Clinical Trials01:12

Statistical Software for Data Analysis and Clinical Trials

Statistical software is pivotal in data analysis and clinical trials by providing tools to analyze data, draw conclusions, and make predictions. These software packages range from simple data management applications to complex analytical platforms, supporting various statistical tests, models, and simulation techniques. Their significance lies in their ability to handle vast amounts of data with precision and efficiency, enabling researchers to validate hypotheses, identify trends, and make...
Analysis Methods of Pharmacokinetic Data: Model and Model-Independent Approaches01:14

Analysis Methods of Pharmacokinetic Data: Model and Model-Independent Approaches

Drug disposition in the body is a complex process and can be studied using two major approaches: the model and the model-independent approaches.
The model approach uses mathematical models to describe changes in drug concentration over time. Pharmacokinetic models help characterize drug behavior in patients, predict drug concentration in the body fluids, calculate optimum dosage regimens, and evaluate the risk of toxicity. However, ensuring that the model fits the experimental data accurately...
Model Approaches for Pharmacokinetic Data: Distributed Parameter Models01:06

Model Approaches for Pharmacokinetic Data: Distributed Parameter Models

Pharmacokinetic models are mathematical constructs that represent and predict the time course of drug concentrations in the body, providing meaningful pharmacokinetic parameters. These models are categorized into compartment, physiological, and distributed parameter models.
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pan-Cancer Drug Response Prediction Using Integrative Principal Component Regression.

Statistics in biosciences·2026
Same author

Targeting the ferritinophagy-lysosome axis as a therapeutic vulnerability in gastroenteropancreatic neuroendocrine tumors.

Cell reports. Medicine·2026
Same author

Impact of <i>SPOP</i> Mutations on Clinical Outcomes in Metastatic Prostate Cancer.

JCO precision oncology·2025
Same author

Splicing of HPV16 E6 promotes aggressive invasion in oropharyngeal cancer via endocytosis of E-cadherin.

bioRxiv : the preprint server for biology·2025
Same author

Genomic alterations and associated outcomes in patients with PSMA-positive metastatic castration-resistant prostate cancer treated with 177Lu-PSMA-617.

The oncologist·2025
Same author

Targeting histone H2B acetylated enhanceosomes via p300/CBP degradation in prostate cancer.

Nature genetics·2025

Related Experiment Video

Updated: Jun 5, 2026

A Novel Bayesian Change-point Algorithm for Genome-wide Analysis of Diverse ChIPseq Data Types
12:39

A Novel Bayesian Change-point Algorithm for Genome-wide Analysis of Diverse ChIPseq Data Types

Published on: December 10, 2012

Functional Integrative Bayesian Analysis of High-dimensional Multiplatform Clinicogenomic Data.

Rupam Bhattacharyya1,2, Nicholas C Henderson3, Veerabhadran Baladandayuthapani3

  • 1Michigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI 48105.

Journal of the American Statistical Association
|June 4, 2026
PubMed
Summary
This summary is machine-generated.

We developed fiBAG, a new framework for analyzing multi-omic data to find disease biomarkers. This method integrates functional genomic data to improve the detection of crucial cellular mechanisms linked to patient survival.

Keywords:
Bayesian variable selectionCancer clinicogenomicsGaussian processesmulti-omic data integrationproteogenomic analyses

More Related Videos

Application of Unsupervised Multi-Omic Factor Analysis to Uncover Patterns of Variation and Molecular Processes Linked to Cardiovascular Disease
08:51

Application of Unsupervised Multi-Omic Factor Analysis to Uncover Patterns of Variation and Molecular Processes Linked to Cardiovascular Disease

Published on: September 20, 2024

Related Experiment Videos

Last Updated: Jun 5, 2026

A Novel Bayesian Change-point Algorithm for Genome-wide Analysis of Diverse ChIPseq Data Types
12:39

A Novel Bayesian Change-point Algorithm for Genome-wide Analysis of Diverse ChIPseq Data Types

Published on: December 10, 2012

Application of Unsupervised Multi-Omic Factor Analysis to Uncover Patterns of Variation and Molecular Processes Linked to Cardiovascular Disease
08:51

Application of Unsupervised Multi-Omic Factor Analysis to Uncover Patterns of Variation and Molecular Processes Linked to Cardiovascular Disease

Published on: September 20, 2024

Area of Science:

  • Genomics
  • Proteomics
  • Computational Biology

Background:

  • Multi-platform molecular and genomics data offer opportunities for disease understanding and treatment.
  • Current multi-omic integration methods need enhanced approaches for detailed cellular function evaluation.
  • Identifying precise cellular functions is crucial for understanding complex disease mechanisms.

Purpose of the Study:

  • To propose a novel framework, fiBAG, for the simultaneous identification of upstream functional evidence of proteogenomic biomarkers.
  • To incorporate functional knowledge into Bayesian variable selection models for improved signal detection.
  • To enhance the understanding of cellular functions governing complex disease mechanisms.

Main Methods:

  • Functional Integrative Bayesian Analysis of High-dimensional Multiplatform Genomic Data (fiBAG) framework.
  • Utilizing Gaussian process models to quantify functional evidence via Bayes factors.
  • Mapping Bayes factors to a calibrated spike-and-slab prior for guided variable selection.

Main Results:

  • Simulations show integrative methods with functional calibration possess higher power for detecting disease-related markers.
  • fiBAG demonstrates profitability in a pan-cancer analysis across 14 cancer types.
  • Identified and assessed cellular mechanisms of proteogenomic markers associated with cancer stemness and patient survival.

Conclusions:

  • fiBAG provides a data-driven approach to evaluate cellular functions and improve biomarker discovery.
  • Integrating functional evidence enhances the detection of biologically relevant markers for patient outcomes.
  • The framework offers a powerful tool for proteogenomic biomarker assessment in cancer research.